

April 23, 2010

Results of Phase III Clinical Trial of HKT-500 in the USA

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President and CEO: Hirotaka Nakatomi) announces a result of a phase III clinical trial of HKT-500 (generic name: ketoprofen), an external-use pain-relieving topical patch, which is being developed in the USA.

Since 2009, we have conducted the phase III clinical trial of HKT-500 for the treatment of ankle sprain. Analyses of the results showed no statistically significant differences between the HKT-500 and placebo groups in the efficacy of the treatment of ankle sprain.

We are now discussing actions to take.

HKT-500 is an external-use pain-relieving topical patch containing ketoprofen and has been developed for marketing in the USA. Its formulation is different from that of Mohrus Tape®, which is currently available in Japan.